Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEMO trial of MEK162 versus dacarbazine in NRAS-mutant advanced melanoma
NL-OMON47339Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing MEK162 with dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Mar 2019; status: active, not recruiting.
02
Drugs
binimetinibdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON47339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47339.